EFPIA, Medicines for Europe and AESGP have called for a Mutual Recognition Agreement on good manufacturing practice in regards to the future relationship between the UK and the EU.
List view / Grid view
Medicines for Europe
Drug shortages can greatly impact patients and the pharmaceutical industry. Adrian van den Hoven, Director General of Medicines for Europe, explains how to prevent and reduce the effects of medicinal scarcities in the EU.
The EC has released a report that has found generics and biosimilars decrease wasteful spending and maintain health quality in the EU.
The associations representing the European and British life science industry have launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union...
New IMS data reveals the growing importance of generic medicines for public health as they now account for 62% of medicines dispensed in Europe delivering huge value while impacting only 4% of total healthcare budgets.
In this Pharmaceutical Packaging In-Depth Focus: End-to-end verification of the medicines supply chain; Understanding the financial implications of the upcoming falsified medicines regulations; Point of view on the evolution of labelling and packaging.